EWTX
Edgewise Therapeutics, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Neutral
+12/100
Last price
40.02
▼ 0.28 (0.69%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
40.00
Prev close
40.30
Day high
41.03
Day low
39.34
Volume
1.62M
Market cap
$4.35B
P/E (TTM)
—
52W range
14.25 – 48.51
Day trading desk
Gap from prior close
-0.74%
Prior close 40.30
VWAP
40.02
+0.00% from price
Relative volume
1.44×
Normal
Session range
11.68%
37.50 – 41.88
Position in range
58%
Mid range
ATR (14D)
2.19
5.46% of price
Prior day high
41.79
PDH
Prior day low
39.98
PDL
Bid / ask spread
—
Quote not published
Session volume
1.95M
Avg 1.36M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+2.12%
+0.2%
1M
-7.08%
-8.2%
3M
-13.56%
-18.1%
6M
+23.14%
+5.0%
YTD
+61.27%
+47.0%
1Y
+155.72%
+139.3%
3Y
+598.43%
+516.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on EWTX open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+43.25K
Net buying
Buy transactions
9
341.91K shares
Sell transactions
7
298.66K shares
Net transactions
+16
Buys less sells
Sell : buy shares
0.9 : 1
Mixed
Insider-held shares
528.90K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 13, 26 | DONOVAN JOANNE M Officer |
SELL | 9.44K | $412.70K | Direct |
| Aug 12, 26 | KOCH KEVIN Chief Executive Officer |
— | 39.84K | — | Direct |
| Aug 12, 26 | MOORE JOHN R General Counsel |
— | 12.50K | — | Direct |
| Aug 12, 26 | DONOVAN JOANNE M Officer |
— | 12.81K | — | Direct |
| Aug 12, 26 | DERAKHSHAN BEHRAD Officer |
— | 13.28K | — | Direct |
| Aug 12, 26 | RUSSELL ALAN J Officer and Director |
— | 12.81K | — | Direct |
| Aug 12, 26 | KOCH KEVIN Chief Executive Officer |
SELL | 17.97K | $785.04K | Direct |
| Aug 12, 26 | MOORE JOHN R General Counsel |
SELL | 5.02K | $219.82K | Direct |
| Aug 12, 26 | DERAKHSHAN BEHRAD Officer |
SELL | 5.10K | $223.42K | Direct |
| Aug 12, 26 | RUSSELL ALAN J Officer and Director |
SELL | 5.90K | $258.04K | Direct |
| Jul 1, 26 | RUSSELL ALAN J Officer and Director |
CONVERSION | 200.00K | $71.19K | Direct |
| Jul 1, 26 | RUSSELL ALAN J Officer and Director |
SELL | 200.00K | $7.88M | Direct |
| Jul 1, 26 | FOX JONATHAN C Director |
STOCK | 319 | $0 | Direct |
| May 5, 26 | DONOVAN JOANNE M Officer |
CONVERSION | 50.00K | $354.00K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARRUTHERS ROBERT MICHAEL |
Chief Financial Officer | 86.16K | Conversion of Exercise of derivative security |
DERAKHSHAN BEHRAD |
Officer | 31.83K | Conversion of Exercise of derivative security |
DONOVAN JOANNE M |
Officer | 8.63K | Sale |
EDRIS BADREDDIN |
Director | 19.82K | Conversion of Exercise of derivative security |
FOX JONATHAN C |
Director | 24.83K | Stock Award(Grant) |
KOCH KEVIN |
Chief Executive Officer | 52.49K | Conversion of Exercise of derivative security |
MOORE JOHN R |
General Counsel | 17.70K | Conversion of Exercise of derivative security |
ORBIMED ADVISORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
RUSSELL ALAN J |
Officer and Director | 31.47K | Conversion of Exercise of derivative security |
THOMPSON PETER A |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
Fundamentals
Market cap$4.35B
Enterprise value$3.89B
Revenue (TTM)—
Gross profit—
EBITDA$-216.77M
Net income$-197.22M
EPS (TTM)$-1.86
Free cash flow$-92.31M
Total cash$460.71M
Total debt$3.59M
Book value / share$4.16
Shares outstanding108.60M
Float74.27M
Short % of float12.38%
Dividend yield0.00%
Beta (5Y)0.36
Valuation & profitability ratios
Trailing P/E—
Forward P/E-22.04
PEG ratio—
Price / sales—
Price / book9.63
EV / revenue—
EV / EBITDA-17.94
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-38.03%
Return on assets-25.03%
Debt / equity0.80
Current ratio16.24
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $151.39M | $126.97M | $90.91M | $54.03M | +19.2% |
| Selling, general & admin | $40.02M | $31.87M | $23.45M | $17.63M | +25.6% |
| Total operating expense | $191.41M | $158.83M | $114.36M | $71.66M | +20.5% |
| Operating income | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -20.5% |
| Net interest income | $23.61M | $25.02M | $14.19M | $4.02M | -5.6% |
| Pre-tax income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -25.4% |
| Net income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -25.4% |
| Net income to common | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -25.4% |
| Basic EPS | -1.63 | -0.42 | -1.57 | -0.31 | -288.1% |
| Diluted EPS | -1.63 | -0.42 | -1.57 | -0.31 | -288.1% |
| EBIT | -$191.41M | -$158.83M | -$114.36M | -$71.66M | -20.5% |
| EBITDA | -$189.14M | -$156.54M | -$112.63M | -$71.12M | -20.8% |
| Basic shares | 102.93M | 94.72M | 63.72M | 63.23M | +8.7% |
| Diluted shares | 102.93M | 94.72M | 63.72M | 63.23M | +8.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $61.15M | $41.67M | $86.10M | $21.99M | +46.8% |
| Cash & short-term investments | $530.11M | $470.17M | $318.39M | $351.95M | +12.7% |
| Total current assets | $543.38M | $475.48M | $327.00M | $357.00M | +14.3% |
| Property, plant & equipment | $9.22M | $11.07M | $12.69M | $9.85M | -16.7% |
| Total assets | $552.60M | $486.82M | $340.04M | $367.10M | +13.5% |
| Total current liabilities | $27.37M | $23.86M | $16.77M | $16.59M | +14.7% |
| Total debt | $3.99M | $4.74M | $5.41M | $4.41M | -15.8% |
| Total liabilities | $30.35M | $27.60M | $21.20M | $20.39M | +9.9% |
| Retained earnings | -$546.37M | -$378.58M | -$244.76M | -$144.60M | -44.3% |
| Shareholder equity | $522.26M | $459.22M | $318.83M | $346.72M | +13.7% |
| Working capital | $516.01M | $451.62M | $310.23M | $340.41M | +14.3% |
| Net tangible assets | $522.26M | $459.22M | $318.83M | $346.72M | +13.7% |
| Shares issued | 106.25M | 94.84M | 70.45M | 63.26M | +12.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$167.79M | -$133.81M | -$100.16M | -$67.64M | -25.4% |
| Depreciation & amortisation | $2.27M | $2.29M | $1.73M | $538.00K | -1.0% |
| Stock-based compensation | $34.75M | $24.71M | $17.56M | $10.92M | +40.6% |
| Change in working capital | -$5.37M | $10.33M | -$1.56M | $4.09M | -152.0% |
| Operating cash flow | -$143.82M | -$109.03M | -$91.95M | -$52.63M | -31.9% |
| Capital expenditure | -$256.00K | -$1.31M | -$5.75M | -$5.55M | +80.5% |
| Investing cash flow | -$32.79M | -$184.66M | $102.89M | -$70.58M | +82.2% |
| Financing cash flow | $196.09M | $249.25M | $53.17M | $129.64M | -21.3% |
| Free cash flow | -$144.07M | -$110.34M | -$97.69M | -$58.18M | -30.6% |
| End cash position | $61.15M | $41.67M | $86.10M | $21.99M | +46.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $47.55M | $42.65M | $43.59M | $37.48M | $33.56M | +11.5% |
| Selling, general & admin | $14.39M | $11.46M | $12.38M | $9.38M | $9.05M | +25.6% |
| Total operating expense | $61.94M | $54.12M | $55.98M | $46.86M | $42.61M | +14.5% |
| Operating income | -$61.94M | -$54.12M | -$55.98M | -$46.86M | -$42.61M | -14.5% |
| Net interest income | $4.62M | $5.10M | $5.76M | $6.19M | $6.50M | -9.5% |
| Pre-tax income | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -17.0% |
| Net income | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -17.0% |
| Net income to common | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -17.0% |
| Basic EPS | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 | -15.2% |
| Diluted EPS | -0.53 | -0.46 | -0.47 | -0.39 | -0.34 | -15.2% |
| EBIT | -$61.94M | -$54.12M | -$55.98M | -$46.86M | -$42.61M | -14.5% |
| EBITDA | -$61.35M | -$53.52M | -$55.40M | -$46.29M | -$42.04M | -14.6% |
| Basic shares | 107.67M | 107.12M | 106.01M | 105.49M | 104.94M | +0.5% |
| Diluted shares | 107.67M | 107.12M | 106.01M | 105.49M | 104.94M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $72.32M | $33.21M | $61.15M | $46.00M | $43.40M | +117.8% |
| Cash & short-term investments | $460.71M | $499.56M | $530.11M | $563.34M | $593.99M | -7.8% |
| Total current assets | $471.52M | $509.79M | $543.38M | $573.90M | $603.25M | -7.5% |
| Property, plant & equipment | $8.17M | $8.73M | $9.22M | $9.57M | $10.08M | -6.4% |
| Total assets | $479.69M | $518.52M | $552.60M | $583.47M | $613.33M | -7.5% |
| Total current liabilities | $29.04M | $22.54M | $27.37M | $21.65M | $20.90M | +28.8% |
| Total debt | $3.59M | $3.79M | $3.99M | $4.18M | $4.37M | -5.4% |
| Total liabilities | $31.61M | $25.32M | $30.35M | $24.82M | $24.26M | +24.9% |
| Retained earnings | -$652.71M | -$595.38M | -$546.37M | -$496.15M | -$455.49M | -9.6% |
| Shareholder equity | $448.08M | $493.20M | $522.26M | $558.65M | $589.07M | -9.1% |
| Working capital | $442.48M | $487.25M | $516.01M | $552.25M | $582.36M | -9.2% |
| Net tangible assets | $448.08M | $493.20M | $522.26M | $558.65M | $589.07M | -9.1% |
| Shares issued | 107.78M | 107.48M | 106.25M | 105.76M | 105.34M | +0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$57.33M | -$49.01M | -$50.22M | -$40.67M | -$36.12M | -17.0% |
| Depreciation & amortisation | $597.00K | $590.00K | $575.00K | $570.00K | $567.00K | +1.2% |
| Stock-based compensation | $9.36M | $8.71M | $9.88M | $8.09M | $7.73M | +7.4% |
| Change in working capital | $5.71M | -$1.82M | $2.66M | -$709.00K | -$2.56M | +413.3% |
| Operating cash flow | -$42.47M | -$42.54M | -$38.59M | -$34.78M | -$32.58M | +0.2% |
| Capital expenditure | -$32.00K | -$260.00K | -$73.00K | -$89.00K | -$50.00K | +87.7% |
| Investing cash flow | $78.49M | $2.43M | $49.76M | $35.72M | -$162.17M | +3,126.1% |
| Financing cash flow | $3.09M | $12.17M | $3.98M | $1.66M | $188.23M | -74.6% |
| Free cash flow | -$42.50M | -$42.80M | -$38.66M | -$34.87M | -$32.63M | +0.7% |
| End cash position | $72.32M | $33.21M | $61.15M | $46.00M | $43.40M | +117.8% |
Options analytics
Put / call volume
0.03
Call-heavy session
Put / call open interest
0.65
Positioning, not flow
Max pain
40.00
-0.0% from spot
ATM implied vol
60.2%
Nearest strike to spot
Skew (10% OTM)
+5.7%
Puts bid over calls
Call volume
3.14K
Contracts, this expiry
Put volume
87
Contracts, this expiry
Heaviest call OI
50.00
3.71K contracts
Heaviest put OI
35.00
3.01K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.47 | -0.53 | -12.2% |
| Mar 2026 | -0.49 | -0.46 | +5.1% |
| Dec 2025 | -0.44 | -0.47 | -6.3% |
| Sep 2025 | -0.40 | -0.39 | +2.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.81 | 10 | $129.17M | 0.0% |
| Next quarter | -0.38 | 12 | $10.42M | 0.0% |
| Current year | 1.38 | 10 | $139.58M | 0.0% |
| Next year | -1.82 | 11 | $42.73M | -69.4% |
Analyst targets & ownership
Mean target$52.62
High target$66.00
Low target$36.00
Implied upside31.47%
Analyst count13
ConsensusBUY
Strong buy / Buy3 / 8
Hold2
Sell / Strong sell0 / 0
Held by insiders0.49%
Held by institutions111.69%
Institutions holding322
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
40.33
-0.78% from price
SMA 20
42.46
-5.74% from price
SMA 50
42.83
-6.57% from price
SMA 100
40.25
-0.58% from price
SMA 200
34.98
+14.42% from price
EMA 12
41.12
-2.67% from price
EMA 26
41.97
-4.65% from price
EMA 50
41.91
-4.50% from price
RSI (14)
41.8
Neutral
MACD (12,26,9)
-0.85
Hist -0.29
ATR (14)
2.19
5.46% of price
Realised vol 30D
41.2%
Annualised
Bollinger upper
47.09
20, 2σ
Bollinger lower
37.82
20, 2σ
50 / 200 cross
Golden
42.83 vs 34.98
Trend bias
Above 200
+14.42%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.28
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
41.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-21.0%
Peak to trough
Max drawdown 5Y
-75.4%
Peak to trough
ATR 14
2.19
5.46% of price
Beta (reported)
0.36
5Y monthly, from filing
Short interest
Shares short
9.54M
Prior 9.68M
Change vs prior
-1.4%
Shorts covering
% of float
12.38%
Elevated
% of shares out
8.79%
Against total outstanding
Days to cover
8.0
Crowded exit
Float
74.27M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 20, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Aug 11, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Jul 20, 26 | Evercore ISI Group | MAINTAINED | Outperform | Outperform |
| Jul 9, 26 | Oppenheimer | INITIATED | — | Outperform |
| Jul 6, 26 | Guggenheim | MAINTAINED | Buy | Buy |
| Jun 17, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 17, 26 | Goldman Sachs | MAINTAINED | Neutral | Neutral |
| Jun 16, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 2, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 2, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Jun 2, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-06
Corporate Changes & Voting Matters
8-K/A · 2026-07-16
Corporate Changes & Voting Matters
8-K · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-05
Corporate Changes & Voting Matters
8-K · 2026-06-01
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEFA14A · 2026-04-23
Corporate Changes & Voting Matters
8-K · 2026-02-26
Headlines
Edgewise Therapeutics (EWTX) Sets EDG 7500 Focus Call, Is It Still 20% Below Fair Value?
Simply Wall St. · 4d ago
Will Camzyos Growth Keep Driving BMY's Cardiovascular Portfolio?
Zacks · 5d ago
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire · 6d ago
Edgewise Therapeutics Could Benefit From Differentiated EDG-7500 Profile, Oppenheimer Says
MT Newswires · 11d ago
Edgewise's EDG-7500 Mechanism Lends Confidence, RBC Says
MT Newswires · 14d ago
Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
PR Newswire · 15d ago
Biotech Options Buzz: UTHR, NMRA, EWTX
Schaeffer's Investment Research · 19d ago
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Zacks · 32d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.